Loading...
Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy
Background: Oral octreotide capsules (OOC; MYCAPSSA(®)) are approved in the US for individuals with acromegaly who responded to and tolerated treatment with injectable somatostatin receptor ligands (iSRLs). Add-on cabergoline therapy has shown effectiveness in patients previously inadequately contro...
Na minha lista:
| Udgivet i: | J Endocr Soc |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8090659/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1058 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|